On 6/15/2021 Cantor Fitzgerald brokerage Boosted the Price Target from Reduce to Overweight $217.00 to $272.00 On 5/18/2021 JPMorgan Chase & Co. brokerage Reiterated Rating from Overweight to Neutral $285.00 to $161.00 On 5/12/2021 B. Riley brokerage Lowered the Price Target from $365.00 to $286.00 On 5/12/2021 HC Wainwright brokerage Lowered the...
Hey guys so NVAX had a nice bounce today from its open at 240 and closed at 273.98. It was a solid day I'm not too happy about the volume though due to it being pretty low. The stock is not going to have a tremendous move if there is no volume. We need to have above average volume to see a nice spike above 300 again. Now with the EU news coming possibly end of...
NVAX stock has had a massive explosion from January where the stock hit 294 a share yesterday. Now I had a prediction that NVAX would break 300 a share by March I think it will be much sooner now. With all the orders and revenue stream that will be produced in 2021, we could see total revenue of 16 billion dollars. I am firmly confident we can reach the same...
📈 LON G D1 🛒Risky entry (1%-2% risk) ~ 178.5 🛒A more reliable entry (2%-3% risk) = above 190.30 🎯Target1 = 209.5 🎯Target2 = 240.80 🛑Stop loss or cancel trade = 159
📈 NVAX LONG D1 🛒BUY above = 156 🎯Target1 = 172 🎯Target2 = 201 🛑Stop loss = 1126 🙈Risk = (1%-2%) #NVAX #NVAXLONG #BUYNVAX
Just re-iterating my previous assertion (guess) that NVAX is on course for massive gains in the long-term. Doesn't mean it's a great company but this pandemic has initiated a similar pattern in the past. They have several great developments in the works: NanoFlu, RSV F, and a COVID-19 vaccine candidate. See my previous posts especially the related one. This is...